Comparing immunoadsorption and plasma exchange for treating Guillain-Barré Syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the safety and efficacy of immunoadsorption compared to plasma exchange in patients diagnosed with Guillain-Barré Syndrome (GBS). The study aims to gather data on the outcomes of both treatment methods to determine which may be more effective for patients. Participants will be monitored for their clinical response and any adverse effects associated with the treatments. The study will include adults aged 18 and older who meet specific diagnostic criteria for GBS.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of Guillain-Barré Syndrome according to the diagnostic criteria proposed by Doorn et al. (Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome, Lancet neurology 2008)
* age 18 years or above

Exclusion Criteria:

* Clinical or laboratory (C-reactive protein 20 mg/l or above, or evidence of nitrite-positive urinary tract infection) evidence of manifest systemic infection
* Intake of angiotensin converting enzyme inhibitor within1 weeks before first treatment
* Other contraindications against immunoadsorption or plasma exchange

Where it's running

• Department of Neurology, University of Ulm
  Ulm, Baden-Wurttemberg, Germany Recruiting

Study contacts

• Principal investigator: Johannes Dorst, Prof — University of Ulm
• Study coordinator: Johannes Dorst, Prof
• Email: johannes.dorst@uni-ulm.de
• Phone: +49 731 177 5285

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Glucose levels during a 6 km loaded march

  We will test how blood sugar changes during a 6 km march carrying 15 kg of equipment in healthy soldiers using continuous glucose monitors.

  Recruiting University of Ulm · Ulm · NCT07543705

• Parental metabolism's imprint on the fetal epigenome in gestational diabetes

  We will see if parents' metabolism during pregnancy is linked to epigenetic changes in the fetus in pregnancies with and without gestational diabetes.

  Recruiting University of Ulm · Ulm, Baden-Wurttemberg · NCT07436195

• How changing thyroid hormone levels affects blood sugar, lipids, and energy use

  This trial will test whether raising or lowering thyroid hormones in people with newly diagnosed Graves' disease or thyroid cancer changes blood sugar, insulin, and lipid metabolism using oral glucose tolerance tests.

  Recruiting University of Ulm · Ulm, Baden-Wurttemberg · NCT07410637

• Once-weekly semaglutide for weight loss in adolescents with monogenic obesity

  This study tests whether once-weekly semaglutide 2.4 mg together with a reduced-calorie diet and increased activity helps adolescents with monogenic obesity lose weight, reduce hunger, and improve quality of life over 68 weeks.

  Recruiting University of Ulm · Paris and 6 other locations · NCT07302802

• Global registry for genetic obesity

  This registry collects health and genetic information from people with genetically confirmed or early-onset severe obesity to see if different genes relate to symptoms, complications, and treatment responses.

  Recruiting University of Ulm · Ulm · NCT07296900

• Immunoadsorption treatment for chronic inflammatory demyelinating polyneuropathy

  This observational study will try immunoadsorption as a next-step treatment for adults with CIDP who do not respond well to IVIg or methylprednisolone.

  Recruiting University of Ulm · Ulm, Baden-Wurttemberg · NCT07154524

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.